• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Pharmaceutical Company Astrazeneca Launches Digital Health Program in Israel

Share:

December 3, 2019

Alongside funding, the program will provide Israeli startups with mentorship and training

London-listed pharmaceutical company AstraZeneca PLC has launched a program for investing in the digital health sector in Israel, AstraZeneca announced Wednesday. As part of the program, called BeyondBio, the company intends to make a first investment estimated at NIS 10 million (approximately $2.8), according to a statement. Alongside funding, the program will provide Israeli startups with mentorship and training.

The program is operated in collaboration with Israel-based venture capital firm Jerusalem Venture Partners (JVP); Israel Initiative 2020 (ii2020), a nonprofit founded by JVP founder Erel Margalit; Maccabitech, the research and innovation wing of Israeli health maintenance organization Maccabi Healthcare Services; Israeli businessman Morris Kahn; the Sagol Fund; and Microsoft.

Source: Calcalistech

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Emergent Connect Acquires TouchstoneNet BillingEmergent Connect Acquires TouchstoneNet Billing
  • COVID-19’s Amplification of Digital Technology in the Patient ExperienceCOVID-19’s Amplification of Digital Technology in the Patient Experience
  • Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology MedicineIsoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine
  • Study: Adheretech’s Smart Pill Bottle Intervention Improves Adherence Without Major Additional ExpenseStudy: Adheretech’s Smart Pill Bottle Intervention Improves Adherence Without Major Additional Expense
  • Temperature-Controlled Packaging Solutions in Healthcare Market Future Prospects 2026Temperature-Controlled Packaging Solutions in Healthcare Market Future Prospects 2026
  • Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, ItalyCatalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy
  • Starboard drops out of Celgene fight as proxy firms back Bristol bidStarboard drops out of Celgene fight as proxy firms back Bristol bid
  • Opportunities in the United States Active Pharmaceutical Ingredients CDMO Market – A USD 49.56 Billion Market by 2026 – ResearchAndMarkets.comOpportunities in the United States Active Pharmaceutical Ingredients CDMO Market – A USD 49.56 Billion Market by 2026 – ResearchAndMarkets.com

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications